ESMO: European Society for Medical Oncology

1. Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs

   New anticancer drugs substantially reduce the risk of death and tumour progression, but only marginally extend patient survival

2. EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab

   It is indicated for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%

3. Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-negative, BRCA-mutated Breast Cancer

   Findings from the single-arm, phase II study

4. Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active Brain Metastases from HER2-positive Breast Cancer

   Findings from the TUXEDO-1 study

5. Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced Rare Gastrointestinal Malignancies

   Findings from the ARCAGEN study (EORTC-1843)